Department of Pathology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 119-129 Passeig Vall d'Hebron, Barcelona, Spain; Translational Molecular Pathology Research Group (VHIR), Hospital Vall d'Hebron, 119-129 Passeig Vall d'Hebron, Barcelona, Spain.
Department of General Surgery, Endocrine Surgery Division, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 119-129 Passeig Vall d'Hebron, Barcelona, Spain.
Endocrinol Diabetes Nutr (Engl Ed). 2021 May;68(5):346-353. doi: 10.1016/j.endinu.2020.04.004. Epub 2020 Aug 14.
The risk of recurrence in papillary thyroid carcinoma (PTC) is likely related to the amount of tumour in the metastatic lymph node (LN). Therefore, the current TNM classification (N0/N1) make it necessary to find a method to quantify the LN metastasis (LNM). We propose that the quantitative molecular assay One-Step Nucleic-Acid Amplification (OSNA), which measures the number of cytokeratin-19 (CK-19) mRNA copies as a marker of LNM, could play this role. Our objective was to describe the characteristics of the LNs from PTC, and to compare the morphological characteristics that have been claimed as criteria for metastatic burden with OSNA.
Prospective study of LNs from 42 patients. All of the LNs were measured, weighed and analysed by OSNA and also by imprint cytology.
A total of 573 LNs were included, 187 (32.6%) of them were OSNA-positives. The global consistency between cytology and OSNA was 87.4%. Significant differences were observed in the CK-19 copy number between the LNMs<0.2cm and those >3cm, as well as between those from 0.2 to 3cm with respect to those >3cm, but not between those <0.2cm and those between 0.2 and 3cm. The total tumour load per neck dissection showed no differences based on whether there were ≤5 or >5 LNMs.
In our series the LNMs >3cm show an increased tumour load, but it is unclear if it is necessary to sub-classify the smaller ones as well as the relevance of the number of metastatic nodes according to the cut-off of 5 nodes. We consider that the OSNA analysis avoids the bias of nodal histology and allows for a greater understanding of its real oncological potential.
甲状腺乳头状癌(PTC)的复发风险可能与转移淋巴结(LN)中的肿瘤量有关。因此,目前的 TNM 分类(N0/N1)需要找到一种方法来量化 LN 转移(LNM)。我们提出,One-Step Nucleic-Acid Amplification(OSNA)定量分子检测,该检测测量角蛋白-19(CK-19)mRNA 拷贝数作为 LNM 的标志物,可能起到这种作用。我们的目的是描述 PTC 的 LNs 特征,并比较被认为是转移负担标准的形态学特征与 OSNA。
对 42 例患者的 LNs 进行前瞻性研究。所有 LNs 均通过 OSNA 和印模细胞学进行测量、称重和分析。
共纳入 573 个 LNs,其中 187 个(32.6%)为 OSNA 阳性。细胞学和 OSNA 之间的总体一致性为 87.4%。在 LNMs<0.2cm 和 >3cm 之间、在 0.2-3cm 之间与 >3cm 之间观察到 CK-19 拷贝数存在显著差异,但在<0.2cm 之间与 0.2-3cm 之间没有差异。根据是否有≤5 个或>5 个 LNMs,每个颈部清扫术的总肿瘤负荷没有差异。
在我们的系列中,>3cm 的 LNMs 显示出肿瘤负荷增加,但尚不清楚是否有必要将较小的肿瘤分类为肿瘤,以及根据 5 个节点的截止值对转移性节点的数量的相关性进行分类。我们认为 OSNA 分析避免了淋巴结组织学的偏倚,并能更好地了解其真实的肿瘤学潜力。